Injex Pharma Inc (fka )

[blackleguan]

Shareholder Newsletter 22/08/12

INJEX Pharma AG has successfully re-launched the needle free injection technology and obtained approvals in important markets
New beauty product SHIREEN will significantly contribute to profitable growth of the company



Dear Shareholder,

With a small team we completed the takeover of the entire worldwide business of INJEX Pharma GmbH. In February 2012, we merged all rights and assets into a corporate shell listed at the open market of the Frankfurt Stock Exchange. We started to set-up a strong professional team.



We managed to install a quality management system according to the ISO 13485 standard. Based on the higher performance level in quality management and product management we were able to speed up national registrations in several important countries. Today, the company has obtained CE Approval, FDA 510(k) registration, the Canadian medical device license, registration in Brazil and a couple of other markets. We also expect to get approval from China in the short term.



INJEX Pharma AG has signed exclusive agreements with dedicated partners worldwide. Some of them started already marketing and sales activities – others will start very soon after the national registration.



The INJEX30 system has moved into the focus of the pharmaceutical industry again. The research and development division of INJEX Pharma AG has some very promising projects in the pipeline and new funding will be used to build up a strong R&D team and to intensify R&D activities.



10 years ago, the market for needle free technology was small and a lot of companies failed to commercialize the technology. Today, this market is larger and has a very high potential. Also medication has changed. Today, the doses of drugs injected are much smaller and this opens up the market for needle free injection, which was limited by the dosage size 10 years ago.



With our new product SHIREEN we are entering the beauty market worldwide. The new poring method is an offer, in particular, to women, who are interested in the rejuvenation of their skin.. When the high priced anti-aging creams do not show any effects anymore, we have a new and innovative way to take care of the skin in a painless way. INJEX Pharma AG is starting in a high margin business on a global scale.



The company has a clear target – to become the worldwide market leader in needle free injection technology. The growth of market capitalization shall confirm our success in the near future. We are planning and we are in preparations to change to a segment with high transparency requirements (General Standard) at the Frankfurt Stock Exchange and to list the company in New York.

http://www.injex.de/newsletterarchiv

Having concentrated on the growth of the company in the past period, we will now - with the news about the Canadian registration and our first contract with an US Partner – move into the next phase and expect to present an interesting news flow to our shareholders.